Despite the advantages of the last decades, median OS for HER2-ve metastatic pts is still 2 years and the choice of treatments is strongly influenced by the drugs used in the adjuvant setting. The use of sequential, single agent chemotherapy (CHT) is strongly recommended by almost all guide lines, even if no data are available regarding the application in the clinical practice. Patients and methods: The AMBRA Study is a longitudinal cohort study, aiming at describing the choice of first and subsequent lines of treatment in HER2-ve ABC pts. For the purposes of the study, we collected data of 30 consecutive pts per centre at first disease relapse in the years 2012-2015, treated with CHT. All pts will be followed up until 12 months after the enrolment of the last patient. Pts metastatic at diagnosis, HER2+ ve tumours or pts treated in a clinical trial for the first relapse were excluded. Considering that 12.000 new cases of ABC are diagnosed each year in Italy and TTC is approximately 8 months, 1200 pts will be representative of the whole population of ABC and of the clinical practice. Results: At the moment of the present analysis, 719 out of 1200 pts have been enrolled. Overall median age at diagnosis of the primary tumour was 62 years (33-90); 55.8% of them were aged 40-59. 46.2% of the tumours were Luminal B and 14.3% TNBC. 632 out of 719 pts (87.9%) have received adjuvant therapy: CHT (68.9%) and/or HT (78.2%). The most used regimens were anthracyclines+ taxanes (25.3%), anthracyclines alone (13.8%) or CMF (10.9%). Median Disease Free Interval was 61 months (1-438). First sites of relapse were viscera in 34.4% of the
Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study
Clara Natoli;
2016-01-01
Abstract
Despite the advantages of the last decades, median OS for HER2-ve metastatic pts is still 2 years and the choice of treatments is strongly influenced by the drugs used in the adjuvant setting. The use of sequential, single agent chemotherapy (CHT) is strongly recommended by almost all guide lines, even if no data are available regarding the application in the clinical practice. Patients and methods: The AMBRA Study is a longitudinal cohort study, aiming at describing the choice of first and subsequent lines of treatment in HER2-ve ABC pts. For the purposes of the study, we collected data of 30 consecutive pts per centre at first disease relapse in the years 2012-2015, treated with CHT. All pts will be followed up until 12 months after the enrolment of the last patient. Pts metastatic at diagnosis, HER2+ ve tumours or pts treated in a clinical trial for the first relapse were excluded. Considering that 12.000 new cases of ABC are diagnosed each year in Italy and TTC is approximately 8 months, 1200 pts will be representative of the whole population of ABC and of the clinical practice. Results: At the moment of the present analysis, 719 out of 1200 pts have been enrolled. Overall median age at diagnosis of the primary tumour was 62 years (33-90); 55.8% of them were aged 40-59. 46.2% of the tumours were Luminal B and 14.3% TNBC. 632 out of 719 pts (87.9%) have received adjuvant therapy: CHT (68.9%) and/or HT (78.2%). The most used regimens were anthracyclines+ taxanes (25.3%), anthracyclines alone (13.8%) or CMF (10.9%). Median Disease Free Interval was 61 months (1-438). First sites of relapse were viscera in 34.4% of theI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
